STAT+: Generics companies fought to stop the new drug pricing law. But they may end up benefiting
WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drug prices. Giving the government such power seemed like an admission that generic medicines don’t do enough to keep costs down.
Now that the changes are law, however, industry experts and lobbyists acknowledge the package is more of a mixed bag for generics makers like Teva and Sandoz, not an existential threat. Though it’s too soon to tell, the law could actually end up encouraging more generic competition, boosting the $435 billion industry.
Continue to STAT+ to read the full story…
Information Courtesy By: John Wilkerson, #HealthcareNews #Healthcare | Feeds
WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drug prices. Giving the government such power seemed like an admission that generic medicines don’t do enough to keep costs down.
Now that the changes are law, however, industry experts and lobbyists acknowledge the package is more of a mixed bag for generics makers like Teva and Sandoz, not an existential threat. Though it’s too soon to tell, the law could actually end up encouraging more generic competition, boosting the $435 billion industry.
Continue to STAT+ to read the full story…
Click For More Details
2023-02-10 15:00
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.